The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


The Journal of Immunology, 1973, 111: 130-136.
Copyright © 1973 by The American Association of Immunologists, Inc.

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bluestein, H. G.
Right arrow Articles by Pierce, C. W.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bluestein, H. G.
Right arrow Articles by Pierce, C. W.

Development of Primary {gamma}M, {gamma}G, and {gamma}A Anti-TNP Plaque-Forming Cell Responses in Vitro1

Harry G. Bluestein2 and Carl W. Pierce3,4,

From The Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115

Abstract

Trinitrophenylated bacteriophage {varphi}X174 (TNP-{varphi}X) is a potent in vitro immunogen capable of stimulating specific anti-TNP plaque-forming cell (PFC) responses in cultures of mouse spleen cells. Under optimal conditions, 10 x 106 spleen cells and 3 x 109 TNP-{varphi}X particles in 1 ml of culture medium, TNP-specific PFC responses representing the major mouse immunoglobulin classes, {gamma}M, {gamma}1, {gamma}2, and {gamma}A were detected. A study of kinetics of appearance of these immunoglobulin class-specific PFC revealed that an increase in {gamma}M PFC was detected within 24 hr of initiation of the cultures; the maximum {gamma}M PFC responses were on days 4 and 5. {gamma}1 and {gamma}2 PFC were not detectable until day 3 of culture and reached maxima on days 5 and 6. The anti-TNP PFC response to TNP-{varphi}X was almost completely suppressed by the addition of 100 µg TNP guinea pig albumin; the addition of free {varphi}X at a 10-fold excess over the TNP-{varphi}X immunogen suppressed the anti-TNP response about 70%.

Footnotes

1 This investigation was supported by United States Public Health Service Research Grants AI-09897 and AI-09920 from the National Institute of Allergy and Infectious Diseases.

2 Present address: Department of Medicine, University Hospital, University of California, San Diego, La Jolla, California 92037.

3 Recipient of United States Public Health Service Research Career Development Award 1K4-AI-70, 173 from the National Institute of Allergy and Infectious Diseases.

4 Address correspondence and reprint requests to Carl W. Pierce, Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1973 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1973 by The American Association of Immunologists, Inc. All rights reserved.